Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Papulopustular Rash

MedGen UID:: 388569
•Concept ID:: C2609319
•: Sign or Symptom

Definition

Skin eruption consisting of papules and pustules, most often appearing in the face, scalp, and upper trunk. It is usually caused by corticosteroids or epidermal growth factor receptor inhibitors. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVPapulopustular Rash

Pathological Conditions, Signs and Symptoms
- Clinical finding
  - Other Finding
    - CTRP Clinical Finding
      - Papulopustular Rash

Professional guidelines

PubMed

Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.

Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T
J Dermatol 2020 Feb;47(2):121-127. Epub 2019 Dec 5 doi: 10.1111/1346-8138.15170. PMID: 31803963

Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.

Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H
Crit Rev Oncol Hematol 2017 Jun;114:102-113. Epub 2017 Apr 11 doi: 10.1016/j.critrevonc.2017.03.032. PMID: 28477738

Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities.

Chu CY, Chen KY, Wen-Cheng Chang J, Wei YF, Lee CH, Wang WM
J Formos Med Assoc 2017 Jun;116(6):413-423. Epub 2017 Mar 27 doi: 10.1016/j.jfma.2017.03.001. PMID: 28351555

See all (11)

Recent clinical studies

Etiology

Evaluation of chemotherapy-induced cutaneous side effects in cancer patients.

Saadet ED, Tek I
Int J Dermatol 2022 Dec;61(12):1519-1526. Epub 2022 Jul 22 doi: 10.1111/ijd.16361. PMID: 35867950

Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.

Yalici-Armagan B, Ayanoglu BT, Demirdag HG
Cutan Ocul Toxicol 2019 Sep;38(3):261-266. Epub 2019 May 7 doi: 10.1080/15569527.2019.1594874. PMID: 31010330

Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.

Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H
Crit Rev Oncol Hematol 2017 Jun;114:102-113. Epub 2017 Apr 11 doi: 10.1016/j.critrevonc.2017.03.032. PMID: 28477738

Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses.

Baldo BA, Pagani M
Immunol Allergy Clin North Am 2014 Aug;34(3):565-96, viii. doi: 10.1016/j.iac.2014.04.003. PMID: 25017678

Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.

Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG
Int J Dermatol 2014 Mar;53(3):376-84. Epub 2013 Jul 24 doi: 10.1111/ijd.12205. PMID: 23879247

See all (21)

Diagnosis

An eosinophilic papulopustular rash in a baby.

Plzáková Z, Bloomfield M, Polášková S, Štork J, Honzík T
Pediatr Dermatol 2020 Jul;37(4):e32-e34. doi: 10.1111/pde.14164. PMID: 32706466

Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.

Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T
J Dermatol 2020 Feb;47(2):121-127. Epub 2019 Dec 5 doi: 10.1111/1346-8138.15170. PMID: 31803963

Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.

Yalici-Armagan B, Ayanoglu BT, Demirdag HG
Cutan Ocul Toxicol 2019 Sep;38(3):261-266. Epub 2019 May 7 doi: 10.1080/15569527.2019.1594874. PMID: 31010330

Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses.

Baldo BA, Pagani M
Immunol Allergy Clin North Am 2014 Aug;34(3):565-96, viii. doi: 10.1016/j.iac.2014.04.003. PMID: 25017678

Non-rash skin toxicities associated with novel targeted therapies.

Lacouture ME, Boerner SA, Lorusso PM
Clin Lung Cancer 2006 Dec;8 Suppl 1:S36-42. doi: 10.3816/clc.2006.s.012. PMID: 17239289

See all (18)

Therapy

Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial.

Amitay-Laish I, Prag-Naveh H, Ollech A, Davidovici B, Leshem YA, Snast I, Popovtzer A, Purim O, Flex D, David M, Brenner B, Ben-Aharon I, Peled N, Hodak E, Stemmer SM
Dermatology 2021;237(6):988-994. Epub 2020 Dec 30 doi: 10.1159/000511869. PMID: 33378750

Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.

Yalici-Armagan B, Ayanoglu BT, Demirdag HG
Cutan Ocul Toxicol 2019 Sep;38(3):261-266. Epub 2019 May 7 doi: 10.1080/15569527.2019.1594874. PMID: 31010330

Side effects of targeted therapies: rash.

Eaby-Sandy B, Lynch K
Semin Oncol Nurs 2014 Aug;30(3):147-54. doi: 10.1016/j.soncn.2014.06.001. PMID: 25085026

Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.

Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG
Int J Dermatol 2014 Mar;53(3):376-84. Epub 2013 Jul 24 doi: 10.1111/ijd.12205. PMID: 23879247

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

Peréz-Soler R, Saltz L
J Clin Oncol 2005 Aug 1;23(22):5235-46. doi: 10.1200/JCO.2005.00.6916. PMID: 16051966

See all (45)

Prognosis

EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.

Nowaczyk J, Fret K, Kaminska-Winciorek G, Rudnicka L, Czuwara J
Anticancer Drugs 2023 Sep 1;34(8):942-948. Epub 2023 Jan 24 doi: 10.1097/CAD.0000000000001494. PMID: 36708507 Free PMC Article

Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.

Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T
J Dermatol 2020 Feb;47(2):121-127. Epub 2019 Dec 5 doi: 10.1111/1346-8138.15170. PMID: 31803963

Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.

Luu M, Boone SL, Patel J, Sullivan P, Rademaker AW, Balagula Y, Lacouture ME
Clin Exp Dermatol 2011 Oct;36(7):733-8. Epub 2011 Jun 21 doi: 10.1111/j.1365-2230.2011.04117.x. PMID: 21689147

Skin toxicities associated with epidermal growth factor receptor inhibitors.

Li T, Perez-Soler R
Target Oncol 2009 Apr;4(2):107-19. Epub 2009 May 19 doi: 10.1007/s11523-009-0114-0. PMID: 19452131

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

Peréz-Soler R, Saltz L
J Clin Oncol 2005 Aug 1;23(22):5235-46. doi: 10.1200/JCO.2005.00.6916. PMID: 16051966

See all (9)

Clinical prediction guides

Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.

Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T
J Dermatol 2020 Feb;47(2):121-127. Epub 2019 Dec 5 doi: 10.1111/1346-8138.15170. PMID: 31803963

Skin Manifestations of Targeted Antineoplastic Therapy.

Sanmartín O
Curr Probl Dermatol 2018;53:93-104. Epub 2017 Nov 7 doi: 10.1159/000479198. PMID: 29131041

Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.

Cignola S, Gonella S, Alessandra B, Palese A
Eur J Oncol Nurs 2016 Feb;20:133-9. Epub 2015 Jul 15 doi: 10.1016/j.ejon.2015.07.003. PMID: 26187661

Non-rash skin toxicities associated with novel targeted therapies.

Lacouture ME, Boerner SA, Lorusso PM
Clin Lung Cancer 2006 Dec;8 Suppl 1:S36-42. doi: 10.3816/clc.2006.s.012. PMID: 17239289

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

Peréz-Soler R, Saltz L
J Clin Oncol 2005 Aug 1;23(22):5235-46. doi: 10.1200/JCO.2005.00.6916. PMID: 16051966

See all (19)